MediciNova Inc. (NASDAQ: MNOV) stock gained by 3.52% at last close while the MNOV stock price surges by 4.12% in the pre-market trading. MediciNova is a clinical-stage biopharmaceutical firm working on new small molecule treatments for inflammatory, fibrotic, and neurodegenerative disorders.
What is happening?
MNOV has stated that it will perform a mouse research to see if MN-166 (ibudilast) is effective in a murine model of chlorine-induced lung damage and death. The study will examine survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histology when mice are subjected to chlorine gas and administered with MN-166 (ibudilast) or control.
This mouse study, as well as a sheep study recently launched, are the result of a collaboration among MediciNova and the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the United States Department of Health and Human Services, to reconfigure MN-166 (ibudilast) as a possible medical form of defense (MCM) against chlorine (ALI).
Federico Gaeta, Chief Scientific Officer of MediciNova, stated,
MNOV is delighted to have reached an agreement to perform a research utilizing greater challenge doses in BARDA’s validated mouse model of chlorine-induced lung damage. This will be the second animal model research to look at MN-166 as a possible therapy for individuals who have been exposed to chemical agents like chlorine. In comparison to control mice, they’ll look at survival rates, clinical state, and lung histological alterations. MN-166 reduced histological alterations in lung tissue, including pulmonary edema, and prevented against pulmonary damage in a prior ARDS animal model research by inhibiting the production of inflammatory cytokines and decreasing cellular death in lung tissue. Because pulmonary edema is a common side effect of chlorine exposure, MN-166 has the potential to enhance health and save lives.